Felix Y. Feng
University of California At San Francisco
I am an Associate Professor of Radiation Oncology. Urology, and Medicine and a member of the Helen Diller Family Comprehensive Cancer Center at the University of California at San Francisco (UCSF). I also serve as Vice Chair for Faculty Development and Director of Translational Research in the Department of Radiation Oncology at UCSF. On a national level, I serve as the Translational Research Program Leader for the Genitourinary Cancer Committee in the NRG/RTOG Cooperative Group and a member of the NCI Genitourinary Cancer Steering Committee.
My research team focuses on clinical and translational studies aimed at improving outcomes for patients with prostate cancer. Our interests include 1) the discovery of prognostic/predictive biomarkers in prostate cancer and 2) the development of rational approaches of targeted treatment for therapy-resistant disease. In particular, my laboratory focuses on sequencing and microarray-based approaches to identify molecular determinants of response from samples from prostate cancer patients treated on clinical trials. We have identified the mechanisms by which genes such as PARP1, DNAPK, SChLAP1, and PCAT1, contribute to prostate cancer progression. We also developed the first clinical-grade biomarker panels that predict prostate cancer response to post-operative radiation and post-operative androgen deprivation, as well as a plasma-based cell-free DNA biomarker that predicts resistance to PARP1 inhibition. In addition, my team has performed key preclinical therapeutic studies that have contributed to the initiation of clinical trials investigating PARP1 inhibitors, DNAPK inhibitors, and bromodomain inhibitors in patients with metastatic castration-resistant prostate cancer.
Sunday, May 20
10:30 AM – 10:45 AM